RFC
FATE icon

Russell Frank Company’s Fate Therapeutics FATE Stock Holding History

Russell Frank Company’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		$71K Buy
+39,300
New +$80.9K ﹤0.01% 2823

Other funds holding FATE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BGA
Belmont Global Advisors Dallas, Texas $106M AUM 2.89% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

Russell Frank Company's FATE Position: Q1 2016 in Review

Russell Frank Company opened a new position in Fate Therapeutics (FATE) in Q1 2016: 39,300 shares worth $71K. The stake represents ﹤0.01% of the portfolio and ranks #2823 among its holdings.

46 funds tracked by Wall St. Rank hold FATE as of Q1 2016.

  • Russell Frank Company held 39,300 shares of Fate Therapeutics worth $71K as of Q1 2016.
  • Fate Therapeutics was a new Russell Frank Company position in Q1 2016.
  • Fate Therapeutics made up ﹤0.01% of Russell Frank Company's portfolio in Q1 2016, its #2823 holding.
  • 46 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2016.

Based on Russell Frank Company's 13F filing for Q1 2016, filed 29 Apr 2016.